title: [Vaccination for human Papillomavirus and erythema multiforme].
authors.affiliation: Service de dermatologie, hôpital Fournier, 36, quai de Bataille, 54000 Nancy, France. jl.schmutz@chu-nancy.fr
authors.forename: J-L
authors.initials: JL
authors.lastname: Schmutz
authors.forename: A
authors.initials: A
authors.lastname: Barbaud
authors.forename: P
authors.initials: P
authors.lastname: Trechot
mesh_terms: D036022:Capsid Proteins / Q000009:adverse effects; D003218:Condylomata Acuminata / Q000517:prevention & control*; D000075202:Contraindications; D003875:Drug Eruptions / Q000175:diagnosis*; D004892:Erythema Multiforme / Q000175:diagnosis*; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007117:Immunization, Secondary; D009856:Oncogene Proteins, Viral / Q000009:adverse effects; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000009:adverse effects*; D012008:Recurrence; D055815:Young Adult
chemical_list: D036022:Capsid Proteins; C114580:HPV L1 protein, Human papillomavirus; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines